Business Wire

Xandr Creates Community

Share

Xandr, AT&T’s advanced advertising and analytics company, has announced the formation of Community, a curated marketplace of publishers that enables advertisers to reach their audiences at scale in a brand-safe, privacy-protected, premium video environment. Community is built on Xandr’s powerful technology and consumer insights, enabling buyers and sellers to drive better business outcomes. This new marketplace is the first-step towards the future convergence of linear TV and digital.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190514005493/en/

Xandr Creates Community (Photo: Business Wire)

Xandr Creates Community (Photo: Business Wire)

Community simplifies and improves an advertiser’s ability to connect with hard-to-reach audiences, regardless of how they engage with content across traditional TV, connected TV, OTT, mobile, and online. Community also offers controls to programmers and publishers to achieve better yield on their premium multiplatform inventory.

“After only eight short months since the launch of Xandr, Community delivers on our promise of a brand-safe, insight-driven, premium video marketplace,” said Brian Lesser, CEO of Xandr. “Building on one of the largest technology platforms in the industry and integrating Xandr’s unique audience insights from AT&T, we created the foundation of Community. Now, with the incredible inventory from our inaugural Community partners, the marketplace is open.”

Community is a Multi-Screen Premium Video Marketplace

Increasingly, marketers are looking for simpler ways to connect with audiences across digital, video, and television.

Xandr is committed to providing advertisers access to scaled, brand-safe, premium content with unique insights across wireless, broadband, and video. By aggregating inventory across publishers and creating multi-seller deals, publishers can increase the value of their inventory and improve monetization, while advertisers have the benefit of better access to content and increased scale.

WarnerMedia (including Otter Media), Vice, Hearst Magazine, Newsy, Philo, Tubi, and Xumo join as inaugural Community partners, adding more than 15 premium content providers to the marketplace and reaching more than 50 million active monthly users on streaming services. In addition to WarnerMedia’s portfolio across CNN, TNT, TBS, truTV, B/R Live, Warner Bros., Crunchyroll, Rooster Teeth and VRV, Community will also encompass additional premium video content from other AT&T owned-and-operated properties including DIRECTV NOW and AT&T WatchTV.

“Community’s vision aligns perfectly with our long-term strategy of pairing our high-quality content with breakthrough insights to deliver better ad experiences and drive results for advertisers,” said Donna Speciale, president of WarnerMedia Ad Sales. “As a launch partner, we are excited to be able to offer clients extended digital audience opportunities through Community, and we look forward to working with Xandr on enhanced addressable solutions with our live national linear television inventory in the near future.”

Added Henry Embleton, head of ad products and strategy, Ellation (part of Otter Media), “We rely on our programmatic partners to deliver the best possible ad supported experience for our fans at Crunchyroll, Rooster Teeth, and VRV, however, that information is not always accurate or reliable. Xandr is going to be a programmatic game changer – delivering deep, rich, dependable data from AT&T to enhance our user experience, paired with an expansive reach to help us grow our bottom line.”

“We're pleased to be working through Community to pair the largest free ad-supported movie and TV audience with unique addressable targeting through AT&T data,” said Mark Rotblat, chief revenue officer, Tubi.

“At Philo, we want to offer the best experience for both our subscribers and advertisers. By partnering with Xandr, we build upon our seamless programmatic solutions that allow advertisers to reach their audiences via the Philo platform,” said Reed Barker, Philo’s head of advertising.

Community is Cross-Screen Addressable

Increasingly, marketers are looking for ways to buy media across multiple touchpoints to connect with hard-to-reach audiences as digital, video, and TV converge. To better power advertising experiences across screens for consumers, Xandr’s Cross-Screen Addressable solution is now integrated within Community, allowing advertisers to combine the power of addressable TV with the precision and scale of digital.

Xandr’s Cross-Screen Addressable solution enables advertisers to define their audience and identify the households that match their desired attributes. Then, through Community, advertisers can serve relevant messages to that same audience across screens to amplify the impact of their campaign.

Community is Accountable

Using Xandr’s data, based on AT&T’s first-party consumer insights, Community will improve the efficacy and efficiency of media buying.

Community is layered with Xandr Audience Segments that are built from AT&T’s 170 million direct-to-consumer relationships. Community’s privacy-forward approach to attribution will enable advertisers to reach their audiences based on intent, interest, and lifestyle attributes.

Similar to the insights advertisers can glean from a Cross-Screen Addressable campaign, Xandr’s unique consumer analytics will help marketers determine the effectiveness of their media buys, including the impact on brand health and the ability to aid in frequency capping of a given brand message. Using these powerful attribution tools, marketers will have the ability to gain greater insights and become more effective with each campaign they run within Community.

Community is Reaching Consumers Where They Are

Xandr recently released original, consumer-centric research, called the Relevance Report. The report surveyed more than 3,000 people to learn how they consume content and their advertising preferences.

Consumers are spending more time than ever engaging with content. The report revealed 68% of consumers spend the majority of their free time engaging with content, and 76% said content enriches and enhances their lives, with 72% stating their day wouldn’t be complete without it.

Despite this engagement with content, consumers, especially younger audiences, have become proficient at tuning out content and advertising that they do not perceive as immediately relevant to them. About 57% of respondents say they do not want to engage with ads because they are not relevant to them and, most importantly, 66% wish advertisements were more relevant to them and their lives.

Community is Making TV More Data-Driven

Xandr is the leader in advanced TV advertising*. Community builds on the expertise of more than 3,000 addressable and advanced TV campaigns, and will begin to incorporate robust TV management tools. Using its technology and data analytics, Community will create more relevant advertising opportunities and help optimize yield management of inventory for live, playback, and VOD on traditional linear TV.

Community is Privacy-Protected

Xandr is committed to protecting data and privacy, while providing valuable and relevant advertising to consumers. Responsible data usage has been part of AT&T’s DNA for more than 143 years, always giving customers the power of choice to opt in or out of relevant advertising.

About Xandr

Xandr is creating a better solution for advertisers and publishers to find and reach specific audiences at scale in trusted, premium content environments. As a current leader in advanced TV advertising with the one of the best technology platforms, AppNexus, we help advertisers deliver the right message, at the right time, on almost any device. We are rooted in a tradition of responsible data usage. For more than 143 years, AT&T has used data and technology to inform and improve the customer experience.

*Source: The Myers Report Survey on Media Company B2B Relationships, Services and Value, Q1 2019.

Contact information

Media
Rob Wheeler, robert.wheeler@xandr.com, 212-837-8121
Kelly Liyakasa, kelly.liyakasa@xandr.com, 347-224-1096

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

bitFlyer Europe and Quazard Partner to Bring First Ever Trading Competition to Botwars Ultimate Trading1.6.2020 07:00:00 EESTPress release

Leading cryptocurrency exchange bitFlyer, is partnering with crypto-trading game developer Quazard, to bring the first ever gamified trading competition to the Botwars Ultimate Trading universe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200531005005/en/ bitFlyer and Quazard bring the first gamified trading competition to the Botwars Ultimate Trading universe (Graphic: Business Wire) The competition, which launches today, allows Botwars players to compete in a free to enter crypto-trading simulator to win real Bitcoin. This is the first trading competition to launch on Botwars, and the only live trading competition of its type. In Botwars Ultimate Trading, players need to build an army of trading robots (each representing a trade) and lead them into battle to conquer the cryptocurrency markets. Botwars is a real-time, gamified currency trading experience where you will learn new trading skills, unlock powerful new tradin

Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time1.6.2020 04:00:00 EESTPress release

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19. The treatment was also able to show improvement in lung lesions to a normal activity level in animal models. The pre-clinical study was conducted in an animal model in collaboration with one of the Korean National Universities, Chungbuk National University College of Medicine. The trial set out to assess the efficacy of two dosage amounts (low and high) for the antiviral antibody treatment. In comparison to the placebo-controlled group, the research team observed improved recovery in terms of clinical symptom scores such as runny nose, cough and body aches, after the first day of treatment. From the fifth day, significant clinical remission was observed. Reverse transcriptase polymerase chain reaction (RT-PCR) measurement and cell culture-based viral diagnosis were used to a

Idriverplus Joins the “Automate with Velodyne” Ecosystem29.5.2020 21:31:00 EESTPress release

Velodyne Lidar, Inc. and Idriverplus today announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. Through the program, Velodyne will further collaborate with Idriverplus to support its continued innovation and promote Idriverplus autonomous vehicles, including street cleaners, passenger cars and logistics vehicles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200529005589/en/ Velodyne Lidar, Inc. and Idriverplus announced an expanded partnership and Idriverplus inclusion into the Automated with Velodyne integrator ecosystem, which helps companies grow their businesses while using Velodyne lidar technology. (Photo: Velodyne Lidar) Recently, Velodyne signed a multi-year sales agreement with Idriverplus to provide Puck™ sensors for the mass production of autonomous vehicles. Idriverplu

Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 56th American Society of Clinical Oncology (ASCO) Annual Meeting and the 25th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is an ongoing, randomized, open-label study prospectively evaluating response-based dosing regimens of ICLUSIG® (ponatinib) over a range of three starting doses (45-, 30-, or 15-mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow-up of approximately 21 months, data from the interim analysis of OPTIC show that the optimal benefit-risk profile for ICLUSIG in patients with CP-CML is achieved with a daily starting dose of 45-mg and, upon achieving ≤1% BCR

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks29.5.2020 15:00:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on a Type II Variation regulatory application and recommended the approval of a pre-filled syringe presentation of TAKHZYRO® (lanadelumab). TAKHZYRO is a subcutaneous injectable prescription medication approved in Europe for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. HAE is a rare genetic disorder that results in recurrent attacks of oedema – swelling – in various parts of the body, including the abdomen, face, feet, genitals, hands and throat.1,2,3 “Our goal is to continuously innovate in all areas of HAE management,” said Isabel Kalofonos, Global Product Strategy Lead, HAE, Takeda. “This positive opinion marks another important step forward as we aim to enhance the experience of treatment administration for peo

Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig® (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings29.5.2020 15:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced that data from the interim analysis of the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial, which was sponsored by Takeda and co-funded by Incyte, will be presented during an oral session at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 – May 31) (Abstract #7502)1; and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 – 14) (Abstract #S172)2. The OPTIC trial is an ongoing randomized, open-label study prospectively evaluating response-based dosing regimens of Iclusig® (ponatinib) over a range of three starting doses (45 mg, 30 mg, 15 mg) with the aim of optimizing its efficacy and safety in patients with chronic-phase chronic myeloid leukemia (CP-CML), who are resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy. With a median follow up of approximately 21 months, data from the interim analysis of the OPTIC trial show that the optimal benefit-r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom